GLYCIPHAGE-VG® Tablets

No Image Found
Composition:

GLYCIPHAGE® VG1: 

Each uncoated bilayered tablet contains:

  • Metformin Hydrochloride I.P.  ……500 mg (in sustained-release form)
  • Voglibose I.P. …………….. 0.2 mg
  • Glimepiride I.P. .………… 1 mg
  • Excipients …………………… q.s.
  • Colours: Lake of Brilliant Blue (C.I. No. 42090) and Lake of Erythrosine (C.I. No. 45430)

 

GLYCIPHAGE® VG2:

Each uncoated bilayered tablet contains:

  • Metformin Hydrochloride I.P. …………… 500 mg (in sustained-release form)
  • Voglibose I.P. ……….…… 0.2 mg
  • Glimepiride. I.P. ….……. 2 mg
  • Excipients …………….…….. q.s.
  • Colours: Ferric Oxide Red and Lake of Brilliant Blue (C.I. No. 42090)

Description

  • The two primary factors leading to Type 2 Diabetes are increased insulin resistance and impaired insulin secretion, which arise from abnormalities within the liver, skeletal muscle and pancreatic cell. This along with the increased absorption of glucose from diet results in a postprandial blood glucose surge that is difficult to control effectively.
  • Metformin hydrochloride improves glucose tolerance by decreasing hepatic glucose production, decreasing gluconeogenesis, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
  • The primary mechanism of action of Glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta-cells.
  • Alpha glucosidase inhibitors (Voglibose) delay glucose absorption at the intestinal level and thereby prevents a sudden surge of glucose post-meal. Hence, the addition of Voglibose to Glimepiride and Metformin sustained- release gives a further augmented, synergistic effect and provides better glycaemic control in the management of Type 2 Diabetes and probably in the prevention of its associated macrovascular and microvascular complications

Indications

  • GLYCIPHAGE-VG® is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with Type 2 Diabetes who are already treated with a combination of glimepiride and metformin and have initially responded to dual therapy but require additional glycaemic control (High Post Prandial Glucose).